DORYX MPC 60 mg
IMPORTANT SAFETY INFORMATION
Doryx Hero

You can Depend on the Doryx® MPC Difference

The DORYX MPC Difference

  • DORYX MPC 60 mg can be taken with or without food or milk
  • Once-daily dosing
  • Flexibile dosing covering up to 240 mg per day
  • Small pill size
  • Contains enteric-coated, delayed-release pellets
Doryx Hero

You can Depend on the Doryx® MPC Difference

The DORYX MPC Difference

  • DORYX MPC 60 mg can be taken with or without food or milk
  • Once-daily dosing
  • Flexibile dosing covering up to 240 mg per day
  • Small pill size
  • Contains enteric-coated, delayed-release pellets

Delayed Release is the Difference

Delayed Release
Formulated to delay the release farther into the GI tract
DORYX (doxycycline hyclate delayed-release tablets)*
DORYX MPC (doxycycline hyclate delayed-release tablets)*
Immediate Release
Formulated to release immediately after ingestion
Seysara® (sarecycline) Tablets*
Targadox® (doxycycline hyclate, USP) Tablets*
Extended Release
Formulated to extend systemicblood levels
Ximino® (minocycline HCI, USP) Extended Release Tablets*
MPC Advantage

The MPC Advantage

According to an AAD survey of HCPs, GI side effects are the #1 reason for noncompliance with oral antibiotics in teenagers*

Doryx MPC
The modified polymer coat (MPC) of DORYX MPC delays drug absorption by approximately 15 to 20 minutes farther in the GI tract as compared to traditional DORYX1-3

DORYX MPC: Bioequivalence Study

DORYX MPC 60 mg tablets are bioequivalent* to DORYX 50 mg tablets1

*Based on 120 mg bioequivalence study

Study design: Open-label, randomized, single-dose, 2-period, 2-treatment, 2-sequence, crossover study under fasting conditions in adults (N=28) comparing DORYX MPC 120 mg to DORYX 100 mg.

Based on serum concentrations of DORYX MPC 120 mg compared with DORYX 100 mg, DORYX MPC 60 mg is bioequivalent to DORYX 50 mg

DORYX MPC 60 mg is bio-equivalent to the DORYX 50 mg

Doryx Table Doryx Table

Disclaimer: Not actual pill size

Doryx Chart

Mean concentration values below LLOQ (<0.1 mcg/mL) in the terminal phase are not plotted.

LLOQ=lower limit of qualification

DORYX MPC Offers Flexible Dosing Options

Doryx Bottle
For DORYX MPC samples, please call 1-800-344-8661 to speak to a representative.
Doryx RX

The usual dosage of DORYX MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.

The maintenance dose may be administered as a single dose or as 60 mg every 12 hours.

Savings and Access

Most insured, eligible patients pay $0* for DORYX MPC 60 mg, 30-120 tablets

Mayne is committed to improving access for your patients.

  • Rapidly expanding Portfolio of Brands, AGs (authorized generics) and Generics
  • Excellent co-pay and cash pay support
  • A national network of 350+ specialty pharmacy partners

‡Restrictions and limitations apply. Please see Terms, Conditions, and Eligibility Criteria of Doryx® MPC Patient Savings Program.

Copay Card
Patients: Download your copay card today!

INDICATION AND USAGE
Doryx® MPC (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of Doryx® MPC and other antibacterial drugs, Doryx® MPC should be used only as indicated.

The usual dosage of Doryx® MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.

IMPORTANT SAFETY INFORMATION
Doxycycline is contraindicated in patients who have shown hypersensitivity to any of the tetracyclines. Tetracycline-class drugs, like Doryx® MPC (doxycycline hyclate delayed-release tablets), can cause fetal harm when administered to a pregnant woman. Doryx® MPC should be avoided if possible by nursing mothers, taking into account the importance of the drug to the mother. Doryx® MPC should not be used in children during tooth development (up to the age of 8 years). Concurrent use of tetracycline-class antibiotics with oral contraceptives may reduce their effectiveness.

Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents including doxycycline, and may range from mild diarrhea to fatal colitis.

Photosensitivity can occur with tetracycline-class drugs. Doryx® MPC patients should minimize or avoid excessive exposure to natural or artificial sunlight, and consider using sunscreen or sunblock. Advise patients to discontinue therapy at the first evidence of skin erythema.

Overgrowth of non-susceptible organisms, including fungi, may occur. Doryx® MPC should be discontinued if superinfection occurs and appropriate therapy instituted.

Intracranial Hypertension (IH) has been associated with the use of tetracyclines. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline-associated IH.

Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia.

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information here.

All registered trademarks are property of their respective owners

References: 1. Data on file. Raleigh, NC; Mayne Pharma. 2. Doryx MPC [package insert]. Raleigh, NC: Mayne Pharma; 2016. 3. Kircik LH, Bikowski JB. Enteric-coated doxycycline pellets, delayed release, in tablets. Pract Dermatol. 2010;(suppl):5-8.